Li Xianzhe, Xiong Zhizhong, Xie Minghao, Huang Qunsheng, Jin Longyang, Yin Shi, Chen Shuanggang, Lan Ping, Lian Lei
Department of Colorectal Surgery, the Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Guangdong Institute of Gastroenterology, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, the Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
J Gastrointest Oncol. 2021 Aug;12(4):1470-1481. doi: 10.21037/jgo-21-61.
Recently, a study from our center indicated that the ratio of preoperative carcinoembryonic antigen (CEA) concentration to maximum tumor diameter (DMAX) may be a prognostic marker for patients with rectal cancer. Therefore, the study aimed to evaluate whether this ratio (CEA/DMAX) has prognostic value for patients with stage II colorectal cancer (CRC).
A prospectively maintained database was searched for patients with pathologically confirmed stage II CRC who underwent surgery between January 2010 and March 2019. Patients were stratified according to the mean CEA/DMAX value into low and high CEA/DMAX groups. Kaplan-Meier, univariable, and multivariable Cox regression analyses were used to evaluate whether the CEA/DMAX could predict overall survival (OS) and disease-free survival (DFS). Nomograms were constructed in terms of the results of multivariable Cox regression analyses.
The study included 2,499 patients with stage II CRC. The mean CEA/DMAX value was 2.33 (ng/mL per cm). Kaplan-Meier analyses revealed that, relative to the low CEA/DMAX group, the high CEA/DMAX group had significantly poorer OS (67.31% 85.02%, P<0.001) and DFS (61.41% 77.10%, P<0.001). The multivariable Cox regression analysis revealed that CEA/DMAX independently predicted OS (hazard ratio: 2.58, 95% confidence interval: 1.51-4.38, P<0.001) and DFS (hazard ratio: 1.97, 95% confidence interval: 1.38-2.83, P<0.001). Two simple-to-use nomograms comprising CEA/DMAX, age, T stage, and lymphovascular invasion were developed to predict 1-, 3-, and 5-year rates of OS and DFS among patients with stage II CRC. The nomograms had good performance based on the concordance index, receiver operating characteristic (ROC) curve analysis, and calibration curves. Subgroup analyses further confirmed that a high CEA/DMAX was associated with poor OS and DFS among patients with stage II colon cancer and among patients with stage II rectal cancer (both P<0.05).
Among patients with stage II CRC, a high CEA/DMAX independently predicted poor OS and DFS, and the predictive abilities were also observed in subgroup analyses of patients with stage II colon cancer or rectal cancer. Furthermore, we developed two nomograms that had good accuracy for predicting the prognosis of stage II CRC.
最近,我们中心的一项研究表明,术前癌胚抗原(CEA)浓度与最大肿瘤直径(DMAX)之比可能是直肠癌患者的一个预后标志物。因此,本研究旨在评估该比值(CEA/DMAX)对Ⅱ期结直肠癌(CRC)患者是否具有预后价值。
在一个前瞻性维护的数据库中,搜索2010年1月至2019年3月期间接受手术的病理确诊Ⅱ期CRC患者。根据CEA/DMAX均值将患者分为低CEA/DMAX组和高CEA/DMAX组。采用Kaplan-Meier法、单变量和多变量Cox回归分析来评估CEA/DMAX是否能预测总生存期(OS)和无病生存期(DFS)。根据多变量Cox回归分析结果构建列线图。
本研究纳入了2499例Ⅱ期CRC患者。CEA/DMAX均值为2.33(ng/mL每厘米)。Kaplan-Meier分析显示,相对于低CEA/DMAX组,高CEA/DMAX组的OS(67.31%对85.02%,P<0.001)和DFS(61.41%对77.10%,P<0.001)明显更差。多变量Cox回归分析显示,CEA/DMAX独立预测OS(风险比:2.58,95%置信区间:1.51 - 4.38,P<0.001)和DFS(风险比:1.97,95%置信区间:1.38 - 2.83,P<0.001)。开发了两个包含CEA/DMAX、年龄、T分期和脉管侵犯的简单易用列线图,以预测Ⅱ期CRC患者1年、3年和5年的OS和DFS率。基于一致性指数、受试者操作特征(ROC)曲线分析和校准曲线,列线图具有良好的性能。亚组分析进一步证实,高CEA/DMAX与Ⅱ期结肠癌患者及Ⅱ期直肠癌患者的OS和DFS较差相关(均P<0.05)。
在Ⅱ期CRC患者中,高CEA/DMAX独立预测OS和DFS较差,且在Ⅱ期结肠癌或直肠癌患者的亚组分析中也观察到了这种预测能力。此外,我们开发了两个列线图,对预测Ⅱ期CRC的预后具有良好的准确性。